BCMA-directed CAR T-cell therapy anitocabtagene autoleucel demonstrated a 76% complete remission rate and 89% negative minimal residual disease in patients with relapsed/refractory multiple myeloma.
Please provide your email address to receive an email when new articles are posted on . Study investigators reported limited high-grade treatment-related CRS or neurotoxicity. More than half of study ...
This interview explores updated efficacy and safety findings from the phase 2 iMMagine-1 trial evaluating anito-cel, a CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma, as ...
So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- ...
Arcellx's anito-cel shows 97% overall response rate and 62% CR/sCR rate in high-risk RRMM patients during Phase 2 iMMagine-1 trial. No severe neurotoxicities observed in over 150 patients dosed, with ...
– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...
Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76 ...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late ...
REDWOOD CITY, Calif. - Arcellx, Inc. (NASDAQ:ACLX) will present three studies on its multiple myeloma cell therapy candidate anitocabtagene autoleucel (anito-cel) at the 2026 Tandem Meetings taking ...
Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results